Cases in point:
Inhibikase Therapeutics C-Abl inhibitor IkT-148009 science.org/doi/10.1126/sci...
"PD, IkT-148009 suppressed c-Abl activation to baseline and substantially protected dopaminergic neurons from degeneration when administered therapeutically by once daily oral gavage beginning 4 weeks after disease initiation. Recovery of motor function in PD mice occurred within 8 weeks of initiating treatment concomitantly with a reduction in α-synuclein pathology in the mouse brain." [emphasis added]
Inhibikase is running a phase 2 trial right now, but they're only accepting patients not taking medication. Further detail here: clinicaltrials.gov/study/NC...
Cinnamon
In this study: Reduction of Lewy Body Pathology by Oral Cinnamon link.springer.com/article/1...
Investigators used 10-month-old A53T mice. These mice are genetically modified to produce defective human alpha synuclein with the A53T mutation. Regarding these mice: alzforum.org/research-model...
"Moreover, around 10 months of age they begin to develop severe motor impairments (Lee et al., 2002). Early signs of impairment include wobbling and posturing."
My report on Cinnamon here: healthunlocked.com/cure-par...
Subtypes: dysphagia
